我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价

摘要

慢性丙型肝炎是一种世界范围流行的慢性进展性疾病,严重威胁人类健康,直接抗病毒药物(DAA)的上市为其治疗带来了革命性的变化.近年来国外已上市多种DAA并取得了良好的疗效,我国亦已陆续批准上市数种并广泛应用于临床,使丙型肝炎治愈率显著上升.通过对我国已上市药物的特点、临床疗效及适应证进行分析,结合已经发表的真实世界中的研究,帮助临床医生根据患者疾病的特点,选择合适的治疗方案.%Chronic hepatitis C (CHC) is a chronic and progressive disease prevalent in the whole world and greatly threatens human health.The launch of direct-acting antiviral agents (DAAs) brings a revolutionary change in the treatment of CHC.In recent years,several DAAs have been marketed in foreign countries and have achieved good clinical effects,and in China,some DAAs have also been approved and widely used in clinical practice,which contributes to the increase in the cure rate of hepatitis C.This article analyzes the features,clinical effects,and indications of DAAs marketed in China and reviews published real-world studies,in order to help clinicians select proper treatment regimens based on patients' features.